Egrifta (Tesamorelin) + AOD-9604 Stack: Safety and Monitoring Guide

What Are These Two Peptides and Why Stack Them?

Tesamorelin and AOD-9604 both target fat reduction through growth-hormone-related pathways, but they act at very different points in that pathway. Tesamorelin drives the upstream GH pulse; AOD-9604 mimics the lipolytic tail of GH itself. That mechanistic separation is the rationale practitioners cite for combining them, even though no published trial has tested the combination in humans.

Tesamorelin (Egrifta): The FDA-Approved Half

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors, amplifies endogenous GH secretion, and raises IGF-1. The FDA approved Egrifta in November 2010 specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy [1]. Its prescribing information sets the approved dose at 2 mg subcutaneously once daily [2].

In the key Phase 3 program, two identical 52-week trials (combined N=543) showed a mean 15.2% reduction in visceral adipose tissue (VAT) by CT scan in the tesamorelin group versus a 5.0% increase in the placebo group [3]. Tesamorelin also significantly reduced trunk fat by DXA and lowered triglycerides in secondary endpoints.

Off-label use for general body-composition improvement is common in anti-aging and telehealth clinics, but this falls outside the labeled indication.

AOD-9604: The Research-Peptide Half

AOD-9604 is a 16-amino-acid fragment corresponding to positions 176 through 191 of human growth hormone, with a tyrosine added to the N-terminus for stability. Early animal research showed the peptide stimulates lipolysis and inhibits lipogenesis in adipocytes through beta-adrenergic signaling without raising IGF-1 or affecting glucose metabolism [4].

Human safety data are limited. A small Phase 2 study in obese adults found AOD-9604 at doses of 1 mg orally daily to be well-tolerated over 12 weeks, but failed to meet its primary weight-loss endpoint compared with placebo [5]. No subcutaneous dosing RCT in humans has been published. The FDA has not approved AOD-9604 for any clinical indication, and compounding pharmacies may not legally market it as a drug under current USP guidelines.

How the Stack Is Theorized to Work

The mechanistic argument for combining these peptides rests on pathway complementarity rather than additive dosing of the same signal.

Upstream vs. Downstream GH Signaling

Tesamorelin acts upstream: it stimulates the pituitary to release more GH, which then raises circulating IGF-1 and activates systemic lipolysis. AOD-9604 acts downstream: it mimics the fragment of GH that directly activates beta-3 adrenergic receptors on adipocytes, bypassing the liver and the IGF-1 axis entirely [4].

This means the two agents are not simply doubling the same signal. Tesamorelin raises IGF-1 by 40 to 50 pg/mL on average [3]; AOD-9604, even in combination, should not add meaningfully to IGF-1 elevation based on its mechanism. That IGF-1 independence is relevant for cancer-risk discussions (see the Safety section below).

Effect on Visceral vs. Subcutaneous Fat

Tesamorelin preferentially reduces visceral adipose tissue. CT-measured VAT fell by 15.2% in the combined Phase 3 analysis, while subcutaneous adipose tissue (SAT) showed only a modest trend [3]. AOD-9604 animal data suggest broader fat-depot activity with no clear visceral selectivity [4]. In theory, stacking them could produce VAT reduction from tesamorelin and broader subcutaneous-fat effects from AOD-9604, though this has not been demonstrated in a human trial.

What Practitioner-Reported Outcomes Actually Say

Clinical forum data and telehealth practitioner reports consistently describe subjective improvements in body composition when AOD-9604 is added to a tesamorelin protocol. These reports are anecdotal. No prospective cohort, no registry, and no observational study has systematically captured outcomes. Practitioners who report using this stack generally describe AOD-9604 at 300 mcg subcutaneously once daily in the morning on an empty stomach, combined with tesamorelin at the labeled 2 mg subcutaneously before bed. The timing separation is intended to avoid receptor competition and to align GH secretion with sleep-phase pulsatility.

Dosing Protocols Cited in Clinical Practice

No published protocol has been validated in a randomized trial. The doses below reflect the Egrifta prescribing information [2] and the highest-studied subcutaneous range extrapolated from animal and early human data.

Tesamorelin Dosing

The FDA-approved dose is exactly 2 mg subcutaneous injection once daily, administered to the abdomen. Reconstitute each vial with 2.2 mL of supplied sterile water and inject within 3 hours. Rotate injection sites within the abdominal area. Patients using tesamorelin off-label for body composition are typically dosed identically to the labeled protocol.

Dose adjustment is not recommended by the prescribing label based on body weight. Some off-label practitioners reduce to 1 mg nightly in patients who develop IGF-1 elevations above the age-adjusted upper limit of normal.

AOD-9604 Dosing

No FDA-approved dose exists. Animal studies used 250 mcg/kg intraperitoneally [4]. Human research used oral formulations at 1 mg daily [5]. Subcutaneous use in clinical practice most commonly appears at 250 to 500 mcg once daily, typically in the morning to avoid temporal overlap with tesamorelin's nighttime injection. Starting at the lower end (250 mcg) for 4 to 6 weeks before titrating is the convention in practitioner reports, though no titration trial exists.

Cycle Length

Tesamorelin trials ran to 52 weeks [3]. Most off-label protocols in clinical practice run 3 to 6 month cycles with a 4-week washout before reassessment. AOD-9604 human data extend only to 12 weeks [5], so longer-term safety beyond that window is unknown.

Safety Profile: What the Evidence Actually Supports

Tesamorelin's Known Adverse Effects

The Egrifta label lists these adverse events occurring in more than 5% of trial participants: peripheral edema, arthralgia, myalgia, injection-site reactions, and fluid retention [2]. These are class effects of GH-pathway activation.

Glucose intolerance is the most clinically significant concern. Tesamorelin raises fasting glucose modestly. In the 52-week trials, HbA1c increased by a mean 0.12% in treated subjects versus 0.02% in placebo [3]. Patients with pre-existing diabetes or impaired fasting glucose require closer monitoring. The label contraindicates tesamorelin in any active malignancy and in pregnancy [2].

IGF-1 elevation is both a biomarker of efficacy and a safety signal. Chronically elevated IGF-1 is associated with increased risk of colorectal, breast, and prostate cancers in epidemiological data [6]. The prescribing label requires IGF-1 monitoring every 3 months and recommends dose reduction or discontinuation if IGF-1 exceeds 3 standard deviations above the age-normalized mean [2].

AOD-9604's Known and Unknown Risks

The 12-week Phase 2 oral trial reported no serious adverse events and adverse-event rates similar to placebo [5]. Subcutaneous injection carries theoretical injection-site risks (erythema, lipoatrophy, infection) common to all peptide injections. Because AOD-9604 does not meaningfully raise IGF-1 [4], cancer-promotion through the IGF-1 axis is considered lower risk than with full-sequence GH analogs. Long-term subcutaneous safety data in humans simply do not exist.

Lipodystrophy from local lipolysis at the injection site is reported anecdotally. Rotating sites is recommended.

Stack-Specific Safety Unknowns

When two agents affect overlapping pathways, the safety unknowns multiply. Key unresolved questions for this stack include:

• Whether combined beta-adrenergic stimulation (AOD-9604) plus elevated GH (tesamorelin) alters glucose homeostasis more than tesamorelin alone
• Whether additive fluid retention occurs
• Whether there are pharmacokinetic interactions (no data exist)
• Long-term cardiovascular implications of sustained GH-pathway upregulation

The absence of data is not evidence of safety. Practitioners and patients must weigh this explicitly.

Monitoring Protocol: Required and Recommended Tests

Baseline Labs Before Starting

Before beginning either agent, the following tests should be obtained and documented:

• Fasting glucose and HbA1c (tesamorelin glucose signal; AOD-9604 oral data showed no glucose effect, but subcutaneous data are absent)
• IGF-1 (age-normalized; required by Egrifta label)
• Fasting lipid panel (tesamorelin lowers triglycerides; this is useful for tracking)
• Comprehensive metabolic panel (hepatic and renal function)
• Testosterone, estradiol, and thyroid panel if concurrent hormone therapy is used
• PSA in males over 40 (GH-pathway effects on prostate)
• Body composition by DEXA or CT VAT measurement if available

Ongoing Monitoring Schedule

The table below summarizes a monitoring schedule consistent with the Egrifta prescribing information [2] and extended to cover AOD-9604's additional unknowns.

| Test | Frequency | |---|---| | IGF-1 | Every 3 months (label-required) | | Fasting glucose | Every 3 months | | HbA1c | Every 6 months | | Lipid panel | Every 6 months | | Comprehensive metabolic panel | Every 6 months | | Blood pressure | Every visit | | Body composition (DEXA or waist circumference) | Every 3 months | | Symptom review (edema, arthralgia, injection-site reactions) | Every visit |

When to Pause or Discontinue

Discontinue tesamorelin and reassess if IGF-1 exceeds 3 SD above the age-adjusted normal range [2]. Pause the stack and evaluate if fasting glucose rises above 126 mg/dL or if HbA1c increases by more than 0.5% from baseline. Any new malignancy diagnosis requires immediate cessation of both agents, given tesamorelin's contraindication in active malignancy [2].

Unexplained edema, carpal tunnel symptoms, or significant joint pain should prompt a 2-week drug holiday with re-evaluation before resuming.

Regulatory and Sourcing Considerations

Tesamorelin (Egrifta) is a Schedule-uncontrolled FDA-approved prescription drug available through licensed pharmacies with a valid prescription [1]. Prescribing it off-label (outside HIV-associated lipodystrophy) is legal for physicians but creates a medicolegal documentation burden.

AOD-9604 occupies a different regulatory space entirely. The FDA has not approved it for any use. Its status as a research chemical means compounding pharmacies cannot legally sell it as a drug product under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act without an active IND. Patients obtaining AOD-9604 outside a registered research protocol are obtaining an unapproved drug, and quality control, sterility, and concentration accuracy cannot be assumed [7].

This regulatory gap is not minor. Impure or mislabeled peptide preparations carry direct injection risks. Practitioners who prescribe or recommend AOD-9604 do so outside their DEA- or state-licensed prescribing authority for a drug product.

Evidence Gaps and What Future Research Could Resolve

The honest summary of current evidence is short: tesamorelin has solid Phase 3 trial data for one population and one endpoint; AOD-9604 has a single failed Phase 2 oral trial in humans; and the combination has zero clinical trial data.

Specific gaps that would change clinical guidance if resolved:

1. A randomized crossover trial comparing tesamorelin alone versus tesamorelin plus subcutaneous AOD-9604 for body-composition endpoints.
2. A 24-week pharmacokinetic study confirming that subcutaneous AOD-9604 does not alter pituitary GH pulsatility or IGF-1 in humans.
3. A registry study tracking glucose, IGF-1, and cardiovascular outcomes in patients using this stack for 12 or more months.

The Endocrine Society's 2019 clinical practice guideline on growth hormone in adults explicitly states: "We suggest against the use of GH or GH-related compounds in healthy adults for anti-aging or athletic performance," citing insufficient safety data for unapproved applications [8]. That guideline predates the current telehealth peptide environment, but the underlying evidence standard it sets remains the benchmark.

The FDA's 2023 guidance on peptide drug products further clarified that peptides derived from naturally occurring sequences are subject to standard new drug approval requirements, reinforcing AOD-9604's unregulated status [7].

Special Populations

Patients with Pre-Diabetes or Type 2 Diabetes

Tesamorelin's modest glucose-raising effect is amplified in individuals with impaired fasting glucose. The 52-week trials excluded patients with poorly controlled diabetes (HbA1c > 8%), and the prescribing label recommends monitoring for worsening glycemia [2]. Adding AOD-9604 does not appear to worsen glucose based on oral trial data [5], but subcutaneous data remain absent. HbA1c monitoring every 3 months rather than 6 is appropriate in this population.

Patients on Concurrent TRT or Hormone Therapy

Growth hormone and testosterone have additive effects on lean mass and overlapping effects on lipolysis. Combining tesamorelin, AOD-9604, and TRT increases the number of unmonitored variables. IGF-1 may rise more than expected because testosterone itself raises IGF-1 production [9]. Monitoring IGF-1 at 6 weeks after any testosterone dose change is prudent, rather than waiting the standard 3-month interval.

Women and Peri/Postmenopausal Considerations

Tesamorelin is approved regardless of sex, but GH secretion dynamics differ by sex and change with estrogen status. Postmenopausal women on estrogen therapy may show different IGF-1 responses. No sex-stratified safety data exist for the tesamorelin-AOD-9604 combination. Women who are pregnant or planning pregnancy should not use tesamorelin (labeled contraindication) [2], and no pregnancy safety data exist for AOD-9604.